Nantahala Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,596,504
| Closed | -$8.75M | – | 130 |
|
|
2023
Q4 | $8.75M | Buy |
1,596,504
+497,429
| +45% | +$2.73M | 0.52% | 36 |
|
|
2023
Q3 | $4.15M | Buy |
1,099,075
+918,978
| +510% | +$3.47M | 0.35% | 51 |
|
|
2023
Q2 | $1.21M | Buy |
+180,097
| New | +$1.21M | 0.12% | 74 |
|
|
2022
Q4 | – | Sell |
-1,249,863
| Closed | -$6.6M | – | 114 |
|
|
2022
Q3 | $6.6M | Sell |
1,249,863
-136,275
| -10% | -$720K | 0.43% | 40 |
|
|
2022
Q2 | $5.88M | Buy |
1,386,138
+472,541
| +52% | +$2M | 0.29% | 44 |
|
|
2022
Q1 | $3.15M | Sell |
913,597
-92,865
| -9% | -$320K | 0.14% | 63 |
|
|
2021
Q4 | $6.7M | Sell |
1,006,462
-220,169
| -18% | -$1.47M | 0.24% | 56 |
|
|
2021
Q3 | $12.2M | Sell |
1,226,631
-39,635
| -3% | -$396K | 0.39% | 39 |
|
|
2021
Q2 | $39.1M | Buy |
1,266,266
+274,024
| +28% | +$8.46M | 1.11% | 14 |
|
|
2021
Q1 | $42.7M | Sell |
992,242
-214,229
| -18% | -$9.22M | 1.25% | 14 |
|
|
2020
Q4 | $54.4M | Buy |
+1,206,471
| New | +$54.4M | 1.69% | 8 |
|